Skip to main content
Literatur
1.
Zurück zum Zitat Buti S, Petrelli F, Ghidini A, Vavassori I, Maestroni U, Bersanelli M. Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis. Clin Transl Oncol. 2020;2020:1–7. Buti S, Petrelli F, Ghidini A, Vavassori I, Maestroni U, Bersanelli M. Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis. Clin Transl Oncol. 2020;2020:1–7.
2.
Zurück zum Zitat Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173–82.CrossRef Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173–82.CrossRef
3.
Zurück zum Zitat Funakoshi T, Shimada YJ. Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis. Acta Oncol. 2013;52(4):691–702.CrossRef Funakoshi T, Shimada YJ. Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis. Acta Oncol. 2013;52(4):691–702.CrossRef
Metadaten
Titel
Immunotherapy‑based combinations versus standard first‑line and hypothyroidism risk
verfasst von
G. Roviello
D. Villari
R. Roudi
Publikationsdatum
20.04.2020
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 9/2020
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-020-02352-4

Weitere Artikel der Ausgabe 9/2020

Clinical and Translational Oncology 9/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.